<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - FDA Recommends Approval of Peanut Allergy Medicine
Image Overlay - FDA Recommends Approval of Peanut Allergy Medicine

FDA Recommends Approval of Peanut Allergy Medicine

FDA Recommends Approval of Peanut Allergy Medicine

Aimmune has developed a new oral immunotherapy designed to enable peanut allergy sufferers to avoid serious allergic reactions if exposed to minor quantities of peanut protein. Palforzia (previously AR101) is a peanut-derived biologic that delivers a daily dose of peanut protein with a consistent protein profile, analyzed to ensure reliable major allergen content. Regular consumption of Palforzia is intended to reduce allergic reactions. There are no treatments for peanut allergy approved by the U.S. Food and Drug Administration (FDA), but that may soon change. Yourway keeps the supply chain moving. We are able to seamlessly manage any inventory through our easy-to-use client portal.

Back to Index
Media

Upcoming Events

Clinical Outsourcing Group (COG)

October 21-22, 2025
Burlingame, California

Precision in Pharma Supply Chain & Logistics Summit

November 17-18, 2025
Revere Hotel Boston Common

Media

Articles

Case study: Coordinating a complex intercontinental shipment on a short timeline

Open chat
Come chat with us!
Hello! How can I help you?